



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

بسم الله الرحمن الرحيم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكرو فيلم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



MONA MAGHRABY



Vit D Assessment in Patients with COVID-19 Virus

Thesis

*Submitted for Partial Fulfillment of Master Degree in
Internal Medicine*

By

Sara Fekry Ali

M.B.B. Ch

Faculty of Medicine -Ain Shams University

Under Supervision of

Prof. Dr. Tarek Mohamed youssef

*Professor of Internal Medicine, Hepatology and Gastroenterology
Faculty of Medicine - Ain Shams University*

**Prof. Dr. Shereen Abo Bakr
Abdelrahman**

*Professor Internal Medicine, Hepatology and Gastroenterology
Faculty of Medicine - Ain Shams University*

Dr. Ahmed Elmetwally Ahmed

*Lecturer of Internal Medicine, hepatology and Gastroenterology
Faculty of Medicine - Ain Shams University*

*Faculty of Medicine
Ain Shams University
2021*

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

سَبِّحْكَ لَا إِلَهَ إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **Allah**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Tarek Mohamed youssef**, Professor of Internal Medicine, Hepatology and Gastroenterology, Faculty of Medicine - Ain Shams University, for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Prof. Dr. Shereen Abo Bakr Abdelrahman**, Professor Internal Medicine, Hepatology and Gastroenterology, Faculty of Medicine - Ain Shams University, for her kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Dr. Ahmed Elmetwally Ahmed**, Lecturer of Internal Medicine, hepatology and Gastroenterology, Faculty of Medicine - Ain Shams University, for his great help, active participation and guidance.*

*I would like to express my hearty thanks to all **my family** for their support till this work was completed.*

Last but not least my sincere thanks and appreciation to all patients participated in this study.

Sara Fekry

List of Contents

Title	Page No.
List of Tables.....	i
List of Figures	v
List of Abbreviations.....	ix
Introduction	1
Aim of the Work	2
Review of Literature	
📖 COVID 19 Virus.....	3
📖 Vitamin D	35
Patients and Methods.....	56
Results.....	67
Discussion	93
Conclusion	100
Recommendations	101
Limitations.....	102
Summary.....	103
References	106
Arabic Summary	--

List of Tables

Table No.	Title	Page No.
Table (1):	Summarizes these drugs, including their possible mechanisms of action, adverse effects, precautions, and recommendations, and lists ongoing registered clinical trials	31
Table (2):	Disease severity classifications were assessed according to the following score (the Republic of Korea, 2020).....	57
Table (3):	Reference range.....	61
Table (4):	Grading of pulmonary affection following by CORDS classification.....	62
Table (5):	Comparison between Mild (no. =20), Moderate (no. =20), Severe (no. =20) and Control (no. =20) regarding Sex	67
Table (6):	Comparison between Mild (no. =20), Moderate (no. =20), Severe (no. =20) and Control (no. =20) regarding Special habits	68
Table (7):	Comparison between Mild (no. =20), Moderate (no. =20), Severe (no. =20) and Control (no. =20) regarding Medical history.....	69
Table (8):	Comparison between Mild (no. =20), Moderate (no. =20), Severe (no. =20) and Control (no. =20) regarding CO-RADS classification.....	70
Table (9):	Comparison between Mild (no. =20), Moderate (no. =20), Severe (no. =20) and Control (no. =20) regarding Age	71
Table (10):	Comparison between Mild (no. =20), Moderate (no. =20), Severe (no. =20) and Control (no. =20) regarding TLC	72

List of Tables *(Cont...)*

Table No.	Title	Page No.
Table (11):	Comparison between Mild (no. =20), Moderate (no. =20), Severe (no. =20), and Control (no. =20) regarding Lymphocytes	73
Table (12):	Comparison between Mild (no. =20), Moderate (no. =20), Severe (no. =20), and Control (no. =20) regarding Neutrophils.....	74
Table (13):	Comparison between Mild (no. =20), Moderate (no. =20), Severe (no. =20) and Control (no. =20) regarding Hemoglobin	75
Table (14):	Comparison between Mild (no. =20), Moderate (no. =20), Severe (no. =20) and Control (no. =20) regarding Platelets.....	76
Table (15):	Comparison between Mild (no. =20), Moderate (no. =20), Severe (no. =20) and Control (no. =20) regarding Neutrophil-lymphocyte ratio.....	77
Table (16):	Comparison between Mild (no. =20), Moderate (no. =20), Severe (no. =20) and Control (no. =20) regarding CRP	78
Table (17):	Comparison between Mild (no. =20), Moderate (no. =20), Severe (no. =20), and Control (no. =20) regarding ESR.....	79
Table (18-a):	Comparison between Mild (no. =20), Moderate (no. =20), Severe (no. =20), and Control (no. =20) regarding BUN	80
Table (18-b):	Comparison between Mild (no. =20), Moderate (no. =20), Severe (no. =20), and Control (no. =20) regarding S. Creatine.....	81

List of Tables *(Cont...)*

Table No.	Title	Page No.
Table (19):	Comparison between Mild (no. =20), Moderate (no. =20), Severe (no. =20) and Control (no. =20) regarding AST	82
Table (20):	Comparison between Mild (no. =20), Moderate (no. =20), Severe (no. =20) and Control (no. =20) regarding ALT	83
Table (21):	Comparison between Mild (no. =20), Moderate (no. =20), Severe (no. =20), and Control (no. =20) regarding Total Bilirubin.....	84
Table (22):	Comparison between Mild (no. =20), Moderate (no. =20), Severe (no. =20) and Control (no. =20) regarding S. Albumin.....	85
Table (23):	Comparison between Mild (no. =20), Moderate (no. =20), Severe (no. =20) and Control (no. =20) regarding FERRITIN.....	86
Table (24):	Comparison between Mild (no. =20), Moderate (no. =20), Severe (no. =20) and Control (no. =20) regarding LDH	87
Table (25):	Comparison between Mild (no. =20), Moderate (no. =20), Severe (no. =20) and Control (no. =20) regarding D-DIMER.....	88
Table (26):	Comparison between Mild (no. =20), Moderate (no. =20), Severe (no. =20) and Control (no. =20) regarding VIT D	89
Table (27):	Relation between VTT D regarding Sex, Special habits, Medical history, and CO-RADS classification.....	90

List of Tables *(Cont...)*

Table No.	Title	Page No.
Table (28):	Correlation between VTT D With Age, TLC, Lymphocytes, Neutrophils, Hemoglobin, Platelets, Neutrophil-lymphocyte ratio, CRP, ESR, BUN, S. Creatine, AST, ALT, Total Bilirubin, S. Albumin, FERRITIN, LDH and D-DIMER.....	91

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Coronavirus morphology.....	3
Figure (2):	Transmission of coronavirus.....	4
Figure (3):	The life cycle of the virus within the host.....	5
Figure (4):	Radiological finding of Covid-19 infection.	11
Figure (5):	Clinical manifestation of covid_19 infection.	11
Figure (6):	Direct invasion of CNS by SARS-CoV-2 through the olfactory system.....	16
Figure (7):	Stroke after the SARS-CoV-2 infection.....	17
Figure (8):	Proposed model for SARS-CoV-2-associated diarrhea.	18
Figure (9):	Forms of vit D.....	35
Figure (10):	Vit D3.	36
Figure (11):	Schematic overview of vitamin D metabolism and functions.....	37
Figure (12):	Vitamin D plays a critical role in calcium homeostasis Accumulating evidence demonstrates that extra-renal synthesis of 1, 25(OH)2D3 is critical for the immunomodulatory function of vitamin D in local tissues	38
Figure (13):	Overview of vitamin D's immunomodulation functions	39
Figure (14):	Vitamin D and T-cell function.	40
Figure (15):	Vit D and Ace 2 activity.....	44
Figure (16):	Antiviral function of vit D.....	46

List of Figures *(Cont...)*

Fig. No.	Title	Page No.
Figure (17):	The virus may enter cells by binding to the ACE2 receptor.	49
Figure (18):	The relationship between VitD, ACE2, and SARS-COV2.....	50
Figure (19):	The binding of SARS-COV-2 to receptors and its entrance into cells depends on a cellular protease; subsequently, the virus involves the angiotensin-convertase enzyme 2 (ACE2) and cellular TMPRSS2 serine protease for protein S priming.	52
Figure (20):	Standard curve.....	61
Figure (21):	Personal protective equipment (PPE).	64
Figure (22):	Nasopharyngeal Swabbing.	65
Figure (23):	Shows the difference between (Mild, Moderate, Severe and Control) regarding Sex.	67
Figure (24):	Shows the difference between (Mild, Moderate, Severe, and Control) regarding Smoker.....	68
Figure (25):	Shows the difference between (Mild, Moderate, Severe, and Control) regarding Medical history.....	69
Figure (26):	Shows the difference between (Mild, Moderate, Severe, and Control) regarding CO-RADS classification.	70
Figure (27):	Shows the difference between (Mild, Moderate, Severe and Control) regarding Age.	71

List of Figures (Cont...)

Fig. No.	Title	Page No.
Figure (28):	Shows the difference between (Mild, Moderate, Severe and Control) regarding TLC.....	72
Figure (29):	Shows the difference between (Mild, Moderate, Severe and Control) regarding <i>Lymphocytes</i>	73
Figure (30):	Shows the difference between (Mild, Moderate, Severe and Control) regarding <i>Neutrophils</i>	74
Figure (31):	Shows the difference between (Mild, Moderate, Severe and Control) regarding <i>Hemoglobin</i>	75
Figure (32):	Shows the difference between (Mild, Moderate, Severe and Control) regarding Platelets.....	76
Figure (33):	Shows the difference between (Mild, Moderate, Severe and Control) regarding Neutrophil-lymphocyte ratio.	77
Figure (34):	Shows the difference between (Mild, Moderate, Severe and Control) regarding CRP.....	78
Figure (35):	Shows the difference between (Mild, Moderate, Severe and Control) regarding ESR.....	79
Figure (36-a):	Shows the difference between (Mild, Moderate, Severe and Control) regarding BUN.....	80

List of Figures (Cont...)

Fig. No.	Title	Page No.
Figure (36-b):	Shows the difference between (Mild, Moderate, Severe and Control) regarding <i>S. Creatine</i>	81
Figure (37):	Shows the difference between (Mild, Moderate, Severe and Control) regarding <i>AST</i>	82
Figure (38):	Shows the difference between (Mild, Moderate, Severe and Control) regarding <i>ALT</i>	83
Figure (39):	Shows the difference between (Mild, Moderate, Severe, and Control) regarding <i>Total Bilirubin</i>	84
Figure (40):	Shows the difference between (Mild, Moderate, Severe, and Control) regarding <i>S. Albumin</i>	85
Figure (41):	Shows the difference between (Mild, Moderate, Severe, and Control) regarding <i>FERRITIN</i>	86
Figure (42):	Shows the difference between (Mild, Moderate, Severe, and Control) regarding <i>LDH</i>	87
Figure (43):	Shows the difference between (Mild, Moderate, Severe and Control) regarding <i>D-DIMER</i>	88
Figure (44):	Shows the difference between (Mild, Moderate, Severe, and Control) regarding <i>VIT D</i>	89
Figure (45):	ROC curve (Case and Control) group regarding <i>VIT D</i>	92